PSTV — Plus Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $11.01m
- $10.70m
- $5.82m
Annual balance sheet for Plus Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 8.35 | 18.4 | 18.1 | 8.55 | 3.61 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 0 | — | — | — | 0.571 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 9.18 | 19.7 | 21.8 | 9.83 | 5.26 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 2.46 | 1.82 | 1.57 | 1.11 | 0.521 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 12.1 | 22 | 23.9 | 11.4 | 6.63 |
| Accounts Payable | |||||
| Payable / Accrued | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.54 | 5.87 | 11.9 | 10.7 | 15.6 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 9.07 | 11.1 | 17.4 | 12.7 | 15.6 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Total Equity | 3.03 | 10.8 | 6.45 | -1.35 | -8.95 |
| Total Liabilities & Shareholders' Equity | 12.1 | 22 | 23.9 | 11.4 | 6.63 |
| Total Common Shares Outstanding |